Abstract 1938P
Background
The prognosis for young patients with papillary thyroid cancer is usually good unless distant metastases occur. Lung metastasis is one of the most common distant metastases of thyroid cancer, but lacks an effective way to predict it. Our aim was to develop a nomogram to predict the possibility of lung metastases in patients with papillary thyroid cancer under 55 years old, considering the genetic background.
Methods
243 patients with papillary thyroid cancer under 55 years old were collected from January 2017 to June 2020 and randomly divided (7:3) into the training (n=170) and validation (n=73) groups. Univariate and multivariate binary logistic regression analyses were conducted, based on which a nomogram related to the risk of lung metastases of thyroid cancer was built in the training group. The nomogram was evaluated by calibration curves and decision curve analysis (DCA), the concordance index (C-index) and area under the receiver operating characteristic (ROC) curve (AUC) in the training and validation groups, respectively.
Results
T stage, Single-side invasion, TERT mutation and BRAF mutation were the independent prognostic factors for the construction of the nomogram. The C-index of the nomogram was 0.89 and 0.88 in the training and validation groups, respectively. The AUC, DAC, and calibration curves for nomogram showed satisfactory results. The cut-off value was 0.229, with a sensitivity of 0.829 and a specificity of 0.793.
Conclusions
A nomogram with good predictive capability has been established and validated, which may do a favor to predict lung metastases of young patients with papillary thyroid cancer in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The science and technology innovation Program of Hunan Province (2023SK4043).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1435P - Immunomodulatory effects and improved survival of PG2 plus preoperative chemoradiotherapy in patients with locally advanced esophageal cancer
Presenter: Lai-Man Mok
Session: Poster session 18
1436P - Better overall survival of male versus female patients with advanced gastric adenocarcinoma
Presenter: Minggui Pan
Session: Poster session 18
1437P - Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
Presenter: Marcia Cruz-Correa
Session: Poster session 18
1438P - First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW
Presenter: Yoon-Koo Kang
Session: Poster session 18
1439P - ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study
Presenter: John Strickler
Session: Poster session 18
1440P - Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): A single-arm, open-label, phase II trial
Presenter: Chao Cheng
Session: Poster session 18
1441P - Clinical application of a machine learning-based pathomics signature for predicting lymph node metastasis in early gastric cancer
Presenter: Weiyao Li
Session: Poster session 18
1442P - Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy
Presenter: Hiroki Osumi
Session: Poster session 18
1444P - Nature trumps nurture: Squamous cell carcinoma remains the leading cause of esophageal cancer in Asian-Americans
Presenter: Shubham Gulati
Session: Poster session 18